Video

Dr. Kalinsky Discusses Biosimilars in Breast Cancer

Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical School, discusses the promise of biosimilars in breast cancer.

Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical School, discusses the promise of biosimilars in breast cancer.

There is a lot of interest in trastuzumab (Herceptin) biosimilars in breast cancer. There are multiple studies ongoing, and in the United States, the trastuzumab biosimilar MYL-1401O (Ogivri; trastuzumab-dkst) was approved in December 2017. This biosimilar is approved for use in patients with HER2-positive cancers, including breast and metastatic gastric cancer. In ongoing trials, SB3 and ABP 980 have shown similar pathologic complete response rates to trastuzumab.

Kalinsky says that globally speaking, biosimilars can have a great impact. If biosimilars are approved and are offered at a lower cost than the originator biologic, then patients in countries without access to the originator biologic may be able to get treatment. The differential in cost and access is what could produce the biggest impact, Kalinsky concludes.

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine